Saltar al contenido
Merck

C6643

Clofibrate

liquid

Sinónimos:

2-(4-Chlorophenoxy)-2-methylpropionic acid ethyl ester, Ethyl 2-(4-chlorophenoxy)-2-methylpropionate, Ethyl 2-(4-chlorophenoxy)isobutyrate

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Cambiar Vistas

Acerca de este artículo

Fórmula empírica (notación de Hill):
C12H15ClO3
Número CAS:
Peso molecular:
242.70
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77
PubChem Substance ID:
EC Number:
211-277-4
Beilstein/REAXYS Number:
1913459
Form:
liquid
Quality level:
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle


form

liquid

Quality Level

color

clear colorless

density

1.14 g/mL at 25 °C (lit.)

originator

Wyeth

storage temp.

2-8°C

SMILES string

CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1

InChI

1S/C12H15ClO3/c1-4-15-11(14)12(2,3)16-10-7-5-9(13)6-8-10/h5-8H,4H2,1-3H3

InChI key

KNHUKKLJHYUCFP-UHFFFAOYSA-N

Gene Information

human ... PPARA(5465)
mouse ... Ppara(19013)

Application

Clofibrate has been used:
  • as a quinolinate phosphoribosyltransferase (QPRT) agonist to study its effects on hepatitis C virus (HCV) infection
  • as peroxisome proliferated activated receptor (PPAR) agonist to study its effects on autophagy in rat liver cells
  • as a hepatotoxicant to study its effects on gene expression in primary rat hepatocytes

Biochem/physiol Actions

Clofibrate is a peroxisome proliferated activated receptor α (PPARα) agonist. It is a fibric acid derivative and has a therapeutic effect on hypertriglyceridemia and hyperlipoproteinemia type III. Clofibrate participates in lowering the very-low-density lipoprotein (VLDL) and cholesterol levels in hyperlipoproteinemia type III patients. It facilitates the decrease of total serum bilirubin concentration in Gilbert′s syndrome.

Features and Benefits

This compound is featured on the Nuclear Receptors (PPARs) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Wyeth. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Packaging

Bottomless glass bottle. Contents are inside inserted fused cone.


Still not finding the right product?

Explore all of our products under


pictograms

CorrosionExclamation mark

signalword

Danger

Hazard Classifications

Acute Tox. 4 Oral - Eye Dam. 1 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Clase de almacenamiento

10 - Combustible liquids

wgk

WGK 3

flash_point_f

235.4 °F - closed cup

flash_point_c

113 °C - closed cup

ppe

Eyeshields, Faceshields, Gloves, type ABEK (EN14387) respirator filter



Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos



K Nadira De Abrew et al.
Toxicology, 328, 29-39 (2014-12-06)
High-content data have the potential to inform mechanism of action for toxicants. However, most data to support this notion have been generated in vivo. Because many cell lines and primary cells maintain a differentiated cell phenotype, it is possible that
Drug treatment of lipid disorders.
R H Knopp
The New England journal of medicine, 341(7), 498-511 (1999-08-12)
Szu-Han Chen et al.
PloS one, 12(11), e0187507-e0187507 (2017-11-03)
We tested the hypothesis that prenatal administration of PPARα agonist clofibrate may permanently increase browning capacity of developing white adipose tissue (WAT). Pregnant C57BL/6J mice were fed a basal diet, without (C) or with 0.5% clofibrate (CF, a PPARα agonist)